常山藥業(300255.SZ)控股股東高樹華質押2507萬股
格隆匯6月2日丨常山藥業(300255.SZ)公佈,公司近日接到控股股東高樹華函告,獲悉高樹華將其所持有公司的2507萬股股份進行質押,本次質押股份佔公司股份總數的2.68%,佔其所持有公司股份總數的7.51%。
公司控股股東未來半年內到期的質押股份數量累計為1671萬股,佔其所持公司股份總數的5.01%,佔公司總股本的1.79%,對應融資餘額為3600萬元,還款資金來源為本次股票質押融資款。剔除前述部分外,公司控股股東未來一年內到期的質押股份數量累計為2507萬股,佔其所持公司股份總數的7.51%,佔公司總股本的2.68%,對應融資餘額為4000萬元,還款資金來源為後續股票質押融資等方式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.